[1]聂泽强,李晓云,马爻芳,等.WT1基因在骨髓增生异常综合征患者外同血中的表达及临床意义[J].陕西医学杂志,2019,(8):977-980.
　NIE Zeqiang,LI Xiaoyun,MA Yaofang,et al.Expression of WT1 gene in patients with Myelodysplastic syndrome[J].,2019,(8):977-980.
点击复制

WT1基因在骨髓增生异常综合征患者外同血中的表达及临床意义
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2019年8期
页码:
977-980
栏目:
基础研究
出版日期:
2019-08-05

文章信息/Info

Title:
Expression of WT1 gene in patients with Myelodysplastic syndrome
文章编号:
DOI:10.3969/j.issn.1000-7377.2019.08.004
作者:
聂泽强; 李晓云; 马爻芳; 方 敏; 鲍 杰
山西省运城市中心医院血液科(运城 044000)
Author(s):
NIE Zeqiang;  LI Xiaoyun;  MA Yaofang;  et al.
Yuncheng Central Hospital, Shanxi Province（Yuncheng 044000）
关键词:
骨髓增生异常综合征; 急性白血病; 国际预后评分系统; WT1基因; 逆转录-聚合酶链反应; 相关性
Keywords:
Key words Myelodysplastic syndrome; Acute leukemia;  International prognosis score system;  WT1 gene; Reverse transcriptase-polymerase chain reaction; Relevance
分类号:
R551.3
文献标志码:
A
摘要:
摘 要 目的：探讨WT1基因在骨髓增生异常综合征（MDS）患者中的表达情况及WT1基因与MDS发病及病情进展的关系。方法：采用逆转录-聚合酶链反应检测48例MDS患者，4例MDS-AL患者和10例正常人外周血中WT1基因的表达，并进行分析。结果：①4例MDS-AL患者的WT1阳性率100%，10例正常人的WT1阳性率0%，48例MDS患者WT1阳性率为27.1%。MDS组、MDS-AL组、对照组两两相比有统计学差异（P＜0.05）。②将MDS按IPSS分组，WT1mRNA的表达水平在高危与中危及低危组之间差异均有统计学意义（P＜0.05），中危与低危组、中危Ⅰ组与中危Ⅱ组之间无统计学差异（P＞0.05）。WT1基因表达水平与IPSS评分值有相关性（r=0.74，P＜0.05）。③WT1基因表达水平与原始细胞百分数密切相关（r=0.66，P＜0.05）。④动态随访2例MDS患者，随着疾病进展，WT1的表达水平逐渐升高。结论：WT1基因在各类型MDS均高表达。WT1基因的表达与疾病的进展呈正相关，WT1基因表达情况与原始细胞百分比及IPSS评分均有明显相关性。其可作为临床上对MDS病情的高危评估，预测病情变化和动态监测治疗效果及判断预后的重要指标之一。
Abstract:
Abstract Objective:The expression and clinical implications of WT1 gene in myelodysplastic syndrome（MDS）were investigated. Methods:The expression of WT1 gene of 48 patients with myelodysplastic syndrome, 4 patients with MDS-AL and 10 normal controls were measured by reverse transcriptase chain reaction (RT-PCR) method and anglicized. Results:①WT1 gene was 100% detected in 4 MDS-AL, whereas not be measured in 10 normal controls. The positive rate of WT1 gene expression in 48 patients with MDS was 27.1 %.The difference between MDS group, MDS-AL group and control group was statistically significant (P＜0.05). ②There was significant difference in the relative expression level of WT1 between the high risk group and the low-moderate risk group (P＜0.05), but no significant difference between Moderate riskⅠand Moderate riskⅡ(P>0.05). Therefore, we find a significant relation between the expression of WT1 and the IPSS score(r=0.74,P＜0.05).③A significant correlation was found between WT1 expression levels and blast cell percentage.(r=0.66,P＜0.05). ④ The followed-up 2 cases of MDS patients with disease progression showed that the level of WT1 expression gradually was increased. Conclusion: The expression of WT1 gene is highly expressed in all types of MDS and might be associated with the development of MDS. WT1 expression levels are remarkable correlated with the amount of WT1 transcripts, the IPSS score and blast cell percentage,so risk assessment of WT1 gene can be used to monitor the disease progression and therapeutic effects in MDS patients.

参考文献/References:

[1] 中华医学会血液学分会.骨髓增生异常综合征诊断与治疗中国专家共识（2014年版）[J]. 中华血液学杂志，2014,35(11):1042-1048.
[2] Call KM,Glaser T,Ito CY, et al. Isolation and characterization of a zinc finger polypep tide gene at the human chromosome 11 Wilms’tumor locus[J]. Cell, 1990, 60(3):509-520.
[3] Menssen HD, Siehl JM, Thiel E. Wilms’tumor gene (WT1) expression as a panleukemic marker[J]. Int J Hematol, 2002,76(2):103-109.
[4] Malagola M, Skert C, Borlenghi E, et al. Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients[J]. Cancer Med, 2016, 5(2):265-274.
[5] Yining Y, Xiaorui W, Chuxian Z, et al. Prognostic significance of diagnosed WT1 level in acute myeloid leukemia: a meta-analysis[J]. Ann Hematol, 2015, 94(6):929-938.
[6] Nomdedéu JF, Hoyos M, Carricondo M, et al. Bone marrow WT1 levels at diagnosis, post-induction and postintensification in adult de novo AML[J]. Leukemia, 2013, 27(11):2157-2164.
[7] 沈 悌, 赵永强. 血液病诊断及疗效标准[M].4版. 北京：科学出版社, 2018:163-170.
[8] 阳勇龙, 朱刚直, 陈小平. Wilms肿瘤易感基因在急性髓系白血病中的研究进展[J]. 中国临床药理学与治疗学, 2016, 21(11):1313-1320.
[9] Xiaodong L, Yaping X, Ruihua M, et al. Overexpression of Wilms tumor 1 gene as a negative prognosti cindicator in acute myeloidleukemia[J]. PLoS One, 2014, 9(3):e92470-e92478.
[10] 万鼎铭, 边志磊, 刘延方, 等. 急性髓系白血病患者骨髓WT1基因的表达与预后的关系[J]. 郑州大学学报：医学版,2014,49(3):386-390.
[11] 郝英婵, 伍 权, 张爱梅, 等. WT-1 mRNA定量分析在急性白血病移植后微小残留病监测中的意义[J]. 临床检验杂志, 2016, 34(5):321-324.
[12] Casalegno-Garduno R, Schmitt A, Spitschak A, et al. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation[J]. Int J Cancer, 2016, 38(7)：1792-1801.
[13] Israyelyan A, Goldstein L, Tsai W, et al. Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation[J]. Bone Marrow Transplant, 2015, 50(1):26-33.
[14] 刘华胜, 朱明山, 张海玲, 等. WT1基因在白血病与非白血病中的表达差异及其临床意义[J]. 中国实验血液学杂志, 2014, 22(5):1217-1221.
[15] Wang Y, Xiao M, Chen X, et al. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation[J]. Mol Cell, 2015, 57(4):662-673.
[16] Rampal R, Alkalin A, Madzo J, et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia[J]. Cell Rep, 2014, 9(5):1841-1855.
[17] 邓春阳，陈 双. 多基因甲基化在骨髓增生异常综合征患者中的预后价值[J]. 中国实验血液学杂志, 2017, 25(4):1118-1122.
[18] 杨颖莹, 杨金花, 王 丹. 骨髓增生异常综合征的生物学特性和预后因素的研究[J]. 中国实验血液学杂志, 2017, 25(4):1113-1117.
[19] 卢 丹, 秦亚溱, 李玲娣, 等. 骨髓增生异常综合征患者骨髓及外周血中WT1及PRAME基因的表达研究[J].中国实验血液学杂志, 2014, 22(2):370-376.

相似文献/References:

[1]董 曼,王月莉.不同剂量地西他滨对骨髓增生异常综合征小鼠Beclin1蛋白表达的影响[J].陕西医学杂志,2021,50(6):657.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.004]
　DONG Man,WANG Yueli.Effects of different doses of decitabine on Beclin1 protein expression in mice with myelodysplastic syndrome[J].,2021,50(8):657.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.004]
[2]李振波,陆 诚.阿扎胞苷治疗骨髓增生异常综合征合并额外性梳样蛋白1基因突变疗效及安全性分析[J].陕西医学杂志,2021,50(9):1135.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.023]
　LI Zhenbo,LU Cheng.Efficacy and safety of azacitidine in treatment of MDS with ASXL1 gene mutation[J].,2021,50(8):1135.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.023]
[3]李荣芳,金 龙,赵立丹.外周血T细胞免疫球蛋白黏蛋白-3和血清乳酸脱氢酶联合检测在骨髓增生异常综合征诊断中的应用价值[J].陕西医学杂志,2021,50(9):1143.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.025]
　LI Rongfang,JIN Long,ZHAO Lidan.Application value of combined detection of peripheral blood TIM-3 and serum LDH in diagnosis of MDS[J].,2021,50(8):1143.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.025]
[4]王美佳,刘虹伶,曾依伶.地西他滨联合HA方案治疗骨髓增生异常综合征疗效及安全性研究[J].陕西医学杂志,2023,52(12):1731.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.023]
　WANG Meijia,LIU Hongling,ZENG Yiling.Efficacy and safety of decitabine combined with harringtonine and cytarabine regimen in treatment of myelodysplastic syndrome[J].,2023,52(8):1731.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.023]
[5]张海燕,唐 岚,廖春淑,等.急性白血病化疗后中性粒细胞缺乏合并感染患者临床特征及血清免疫因子检测临床意义[J].陕西医学杂志,2024,(2):239.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.020]
　ZHANG Haiyan,TANG Lan,LIAO Chunshu,et al.Clinical characteristics and clinical significance of serum immune factors in acute leukemia patients with post-chemotherapy neutropenia complicated with infection[J].,2024,(8):239.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.020]
[6]马丽丽,付长江.存活素和细胞周期素依赖性蛋白激酶抑制因子2B在骨髓增生异常综合征诊断及患者预后评估中的临床价值研究[J].陕西医学杂志,2024,(3):348.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.013]
　MA Lili,FU Changjiang.Clinical value of Survivin and P15INK4B in diagnosis of myelodysplastic syndrome and prognosis evaluation of patients[J].,2024,(8):348.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.013]

更新日期/Last Update: 2019-08-13